Cellestis

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Qiagen today said that it has completed the acquisition of all of the ordinary shares of Melbourne, Australia-based Cellestis for A$3.80 (US$4.04) per share.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Cellestis announced on Tuesday that the Supreme Court of Victoria in Australia has approved Qiagen's acquisition of its ordinary shares by way of a Scheme of Arrangement.

Shareholders overwhelmingly approved an amended proposal that will result in Qiagen paying around $374 million to acquire the Australian firm.

Qiagen's offer represents a premium of roughly 41 percent premium to the three-month volume-weighted average price of Cellestis' shares ending on April 1.

With the help of QuantiFeron tests in the first-line setting, Qiagen is hoping to improve the capabilities of its DNA and RNA diagnostics in preventing and profiling disease and delivering personalized care.

The deal provides Qiagen with access to Cellestis' QuantiFeron "pre-molecular" testing technology for detecting and monitoring disease.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.